Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 9Recurrence 1Neoplasms, Plasma Cell 1Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 17Dexamethasone 15Bortezomib 14fludarabine phosphate 12Melphalan 12Lenalidomide 10fludarabine 9Filgrastim 8pomalidomide 7Tacrolimus 7Peripheral Blood Stem Cell Transplantation 7Rituximab 6Radiotherapy 6Etoposide 6Whole-Body Irradiation 5Cord Blood Stem Cell Transplantation 5Calcium Dobesilate 5Busulfan 5Antilymphocyte Serum 5sargramostim 4Sirolimus 4Panobinostat 4Mycophenolic Acid 4Methylprednisolone 4Cyclosporine 4carfilzomib 3Vorinostat 3Stem Cell Transplantation 3Prednisone 3Methotrexate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms, Plasma Cell × elotuzumab × Clear all
NCT04614636 2023-09-21

FT538 in Subjects With Advanced Hematologic Malignancies

Fate Therapeutics

Phase 1 Terminated
42 enrolled
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Leukemia, Myeloid, Acute, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡